1. Type 2 Diabetes Treatment
A novel treatment for type 2 diabetes based on dual SGLT1/2 inhibition is currently being prepared for entry into Phase 3 clinical development. The program aims to develop a next-generation oral therapy that addresses the limitations of existing treatment options.
2. Solid Tumor Treatment
A novel SOS1 inhibitor with broad Pan-RAS activity targeting RAS-mutant cancers is currently undergoing GLP toxicology studies. The program is being developed as part of the Korea Drug Development Fund (KDDF).
3. Anti-fibrotic&Anti-inflammatory Treatment
A novel therapeutic agent with dual antifibrotic and anti-inflammatory activity is currently in the candidate selection stage. The program is being conducted as part of the Korea Drug Development Fund (KDDF).
4. Obesity Treatment
A novel treatment for obesity based on a differentiated mechanism of action is currently in the lead candidate selection stage. The program is focused on developing an innovative therapeutic option for obesity.
